Last update 02 May 2026

JWK-002

Overview

Basic Info

Drug Type
AAV based gene therapy
Synonyms
Recombinant adeno-associated virus 8 (AAV8) expressing human retinoschisin (RS1) gene (Genevector), JWK 002, JWK002
Target
XLRS1
Action
stimulants
Mechanism
XLRS1 stimulants(Retinoschisin stimulants)
Therapeutic Areas
Congenital DisordersEye DiseasesOther Diseases
Active Indication
Retinoschisis
Inactive Indication-
Originator Organization
Chengdu Genevector Biotechnology Co. Ltd.Chengdu Genevector Biotechnology Co. Ltd.
Active Organization
Chengdu Genevector Biotechnology Co. Ltd.Chengdu Genevector Biotechnology Co. Ltd.
West China HospitalWest China Hospital
Inactive Organization-
License Organization-
Drug Highest PhasePhase 1/2
First Approval Date-
RegulationOrphan Drug (United States), Rare Pediatric Disease (United States)
Login to view timeline

Related

4
Clinical Trials associated with JWK-002
ChiCTR2500103933
/ Not yet recruitingPhase 1/2IIT
A Phase I/II Clinical Trial to Evaluate the Safety, Tolerability, and Preliminary Efficacy of JWK002 in Patients with X-linked Retinoschisis (XLRS)
NCT06345898
/ RecruitingEarly Phase 1IIT
Clinical Study on the Safety and Efficacy of JWK002 Injection Administered as a Single Subretinal Injection in Subjects With X-linked Retinoschisis
ChiCTR2300076682
/ RecruitingNot ApplicableIIT
Clinical study on the safety and efficacy of JWK002 injection administered as a single subretinal injection in subjects with X-linked retinoschisis
100 Clinical Results associated with JWK-002
Login to view more data
100 Translational Medicine associated with JWK-002
Login to view more data
100 Patents (Medical) associated with JWK-002
Login to view more data
100 Deals associated with JWK-002
Login to view more data

R&D Status

10 top R&D records.
Login
to view more data
IndicationHighest PhaseCountry/LocationOrganizationDate
RetinoschisisPhase 2
China
Chengdu Genevector Biotechnology Co. Ltd.Chengdu Genevector Biotechnology Co. Ltd.
26 Jun 2025
Login to view more data

Clinical Result

Indication
Phase
Evaluation
View All Results
Study
Phase
PopulationAnalyzed EnrollmentGroupResultsEvaluationPublication Date
NCT06345898 (NEWS)
Phase 1
RS1突变
4
gvskkiatcd(bkdoymbyzv) = ngkrqmzcsl vjwvuwczcc (mmnojmufzg )
View more
Positive
06 May 2024
Login to view more data

Translational Medicine

Boost your research with our translational medicine data.
login
or
view full example data
Boost your research with our translational medicine data.

Deal

Boost your decision using our deal data.
login
or
view full example data
Boost your decision using our deal data.

Core Patent

Boost your research with our Core Patent data.
login
or
view full example data
Boost your research with our Core Patent data.

Clinical Trial

Identify the latest clinical trials across global registries.
login
or
view full example data
Identify the latest clinical trials across global registries.

Approval

Accelerate your research with the latest regulatory approval information.
login
or
view full example data
Accelerate your research with the latest regulatory approval information.

Regulation

Understand key drug designations in just a few clicks with Synapse.
login
or
view full example data
Understand key drug designations in just a few clicks with Synapse.
AI Agents Built for Biopharma Breakthroughs
Accelerate discovery. Empower decisions. Transform outcomes.
Get started for free today!
Accelerate Strategic R&D decision making with Synapse, PatSnap’s AI-powered Connected Innovation Intelligence Platform Built for Life Sciences Professionals.
Start your data trial now!
Synapse data is also accessible to external entities via APIs or data packages. Empower better decisions with the latest in pharmaceutical intelligence.
Bio
Bio Sequences Search & Analysis
Sign up for free
Chemical
Chemical Structures Search & Analysis
Sign up for free